|
[1]
|
Dameshek, W. (1951) Some Speculations on the Myeloproliferative Syndromes. Blood, 6, 372-375.
|
|
[2]
|
Kaushansky, K. (2005) On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense. Blood, 105, 4187-4190.
https://doi.org/10.1182/blood-2005-03-1287
|
|
[3]
|
Tefferi, A. (2010) Novel Mutations and Their Functional and Clinical Relevance in Myeloproliferative Neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-1138.
https://doi.org/10.1038/leu.2010.69
|
|
[4]
|
Kim, S.Y., Im, K., Park, S.N., et al. (2015) CALR, JAK2, and MPL Mutation Profiles in Patients with Four Different Subtypes of Myeloproliferative Neoplasms Primary Myelofibrosis, Essential Thrombocythemia, Pol-ycythemia Vera, and Myeloproliferative Neoplasm, Unclassifiable. American Journal of Clinical Pathology, 143, 635-644.
https://doi.org/10.1309/AJCPUAAC16LIWZMM
|
|
[5]
|
Tefferi, A., Thiele, J., Orazi, A., et al. (2007) Proposals and Rationale for Revision of the World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Recommendations from an Ad Hoc International Expert Panel. Blood, 110, 1092-1097.
https://doi.org/10.1182/blood-2007-04-083501
|
|
[6]
|
Byun, J.M., Kim,Y.J., Youk, T. et al. (2016) Real World Epidemiology of Myeloproliferative Neoplasms: A Population Based Study in Korea 2004-2013. Annals of Hematology, 96, 373-381.
https://doi.org/10.1007/s00277-016-2902-9
|
|
[7]
|
Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. and Tefferi, A. (2006) Essential Thrombocythemia beyond the First Decade: Life Expectancy, Long-Term Complication Rates, and Prognostic Factors. Mayo Clinic Proceedings, 81, 159-166.
https://doi.org/10.4065/81.2.159
|
|
[8]
|
Scherber, R.M., Geyer, H.L. and Mesa, R.A. (2014) Quality of Life in MPN Comes of Age as a Therapeutic Target. Current Hematologic Malignancy Reports, 9, 324-330.
https://doi.org/10.1007/s11899-014-0239-9
|
|
[9]
|
Scherber, R., Dueck, A.C., Johansson, P., et al. (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 Patients. Blood, 118, 401-408.
https://doi.org/10.1182/blood-2011-01-328955
|
|
[10]
|
Mesa, R.A., Niblack, J., Wadleigh, M., et al. (2007) The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet-Based Survey of 1179 MPD Patients. Cancer, 109, 68-76.
https://doi.org/10.1002/cncr.22365
|
|
[11]
|
Scherber, R.M., Kosiorek, H.E., Senyak, Z., et al. (2016) Comprehensively Under-standing Fatigue in Patients with Myeloproliferative Neoplasms. Cancer, 122, 477-485.
https://doi.org/10.1002/cncr.29753
|
|
[12]
|
Saini, K.S., Patnaik, M.M. and Tefferi, A. (2010) Polycythemiavera-Associated Pruritus and Its Management. European Journal of Clinical Investigation, 40, 828-834.
https://doi.org/10.1111/j.1365-2362.2010.02334.x
|
|
[13]
|
Siegel, F.P., Tauscher, J. and Petrides, P.E. (2013) Aquagenic pruritus in Polycythemia vera: Characteristics and Influence on Quality of Life in 441 Patients. American Journal of Hematology, 88, 665-669.
https://doi.org/10.1002/ajh.23474
|
|
[14]
|
Mc Fariand, D.C., Polizzi, H., Mascarenhas, J., et al. (2016) Psychological Symptoms among Patients with BCR- ABL-Negative Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network, 14, 1563- 1570.
|
|
[15]
|
Mesa, R.A., Schwager, S., Radia, D., et al. (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-Based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis. Leukemia Research, 33, 1199-1203.
|
|
[16]
|
Emanuel, R.M., Dueck, A.C., Geyer, H.L., et al. (2012) Myeloproliferative Neoplasm (MPN) Symp-tom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring Sys-tem among Patients with MPNs. Journal of Clinical Oncology, 30, 4098-4103.
https://doi.org/10.1200/JCO.2012.42.3863
|
|
[17]
|
徐俊卿, 徐泽锋, 王静雅, 等. 615例ph染色体/BCR-ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估[J]. 中华血液学杂志, 2016, 37(01): 26-29.
|
|
[18]
|
Ruben, M., Carole, B., Maureen, T., et al. (2016) Myeloproliferative neoplasms (MPNs) Have a Significant Impact on Patients’ Overall Health and Productivity: the MPN Landmarksurvey. BMC Cancer, 16, 167.
https://doi.org/10.1186/s12885-016-2208-2
|
|
[19]
|
Cervantes, F., Dupriez, B., Pereira, A., et al. (2009) New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
https://doi.org/10.1182/blood-2008-07-170449
|
|
[20]
|
Passamonti, F., Cervantes, F., Vannucchi, A.M., et al. (2010) A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: A Study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703-1708.
https://doi.org/10.1182/blood-2009-09-245837
|
|
[21]
|
Gangat, N., Caramazza, D., Vaidya, R., et al. (2011) DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information Fromkaryotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 29, 392-397.
https://doi.org/10.1200/JCO.2010.32.2446
|
|
[22]
|
Passamonti, F., Thiele, J., Girodon, F., et al. (2012) A Prognostic Model to Predict Survival in 867 World Health Organization-Defined Essential Thrombocy-Themia at Diagnosis: A Study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 120, 1197-1201.
https://doi.org/10.1182/blood-2012-01-403279
|
|
[23]
|
Tefferi, A., Rumi, E., Finazzi, G., et al. (2013) Survival and Prognosis among 1545 Patients with Contemporary Polycythemia Vera: An International Study. Leukemia, 27, 1874-1881.
https://doi.org/10.1038/leu.2013.163
|
|
[24]
|
Geyer, H.L., Scherber, R.M., Dueck, A.C., et al. (2014) Distinct Clustering of Symptomatic Burden among Myeloproliferative Neoplasm Patients: Retrospective Assessment in 1470 Patients. Blood, 123, 3803-3810.
https://doi.org/10.1182/blood-2013-09-527903
|
|
[25]
|
Anderson, L.A., James, G., Duncombe, A.S., et al. (2015) Myeloprolifera-tive Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls. American Journal of Hematology, 90, 864- 870.
https://doi.org/10.1002/ajh.24098
|
|
[26]
|
Mesa, R.A., Scherber, R.M. and Geyer, H.L. (2015) Reducing Symptom Burden in Patients with Myeloproliferative Neoplasms in the Era of Janus Kinase Inhibitors. Leukemia & Lymphoma, 56, 1989-1999.
https://doi.org/10.3109/10428194.2014.983098
|
|
[27]
|
Ruben, A., Mesa, M.D., Carole, B., et al. (2017) Differences in Treatment Goals and Perception of Symptom Burden between Patients with Myeloproliferative Neoplasms (MPNs) and Hematolo-gists/Oncologists in the United States: Findings from the MPN Landmark Survey. Cancer, 123, 449-458.
https://doi.org/10.1002/cncr.30325
|
|
[28]
|
Spivak, J.L., Considine, M., Williams, D.M., et al. (2014) Two Clinical Phenotypes in Polycythemia Vera. The New England Journal of Medicine, 371, 808-817.
https://doi.org/10.1056/NEJMoa1403141
|
|
[29]
|
Geyer, H.L., Kosiorek, H., Dueck, A.C., et al. (2017) Associations between Gender, Disease Features and Symptom Burden in Patients with Myeloproliferative Neoplasms: An Analysis by the MPN QOL International Working Group. Haematologica, 102, 85-93.
https://doi.org/10.3324/haematol.2016.149559
|
|
[30]
|
Frödin, U., Lotfi, K. and Fomichov, V. (2015) Frequent and Long-Term Follow-Up of Health-Related Quality of Life Following Allogeneic Haematopoietic Stem Cell Transplantation. European Journal of Cancer Care, 24, 898-910.
https://doi.org/10.1111/ecc.12350
|
|
[31]
|
Krupski, C. and Jagasia, M. (2015) Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead. Current Hematologic Malignancy Reports, 10, 183-191.
https://doi.org/10.1007/s11899-015-0265-2
|
|
[32]
|
Song, C.E. and So, H.S. (2015) Factors Influencing Changes in Quality of Life in Patients undergoing Hematopoietic Stem Cell Transplantation: A Longitudinal and Multilevel Analysis. Journal of Korean Academy of Nursing, 45, 694- 703.
https://doi.org/10.4040/jkan.2015.45.5.694
|
|
[33]
|
Verstovsek, S., Mesa, R.A., Gotlib, J., et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. The New England Journal of Medicine, 366, 799-807.
https://doi.org/10.1056/NEJMoa1110557
|
|
[34]
|
Harrison, C., Kiladjian, J.-J., Al-Ali, H.K., et al. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798.
https://doi.org/10.1056/NEJMoa1110556
|
|
[35]
|
Bryan, J.C. and Verstovsek, S. (2016) Overcoming Treatment Challenges in Myelofibrosis and Polycythemia Vera: The Role of Ruxolitinib. Cancer Chemotherapy and Pharmacology, 77, 1125-1142.
https://doi.org/10.1007/s00280-016-3012-z
|
|
[36]
|
Chen, Y.-Y., Huang, C.-E., Lee, K.-D., et al. (2016) Clinical Efficacy and Safety of Ruxolitinib in the Management of Myelofibrosis: A Single Institution Experience in Taiwan. Hematology, 21, 3-9.
https://doi.org/10.1179/1607845415Y.0000000036
|
|
[37]
|
李仕能. 凉血解毒, 活血理气方治疗原发性血小板增多症(血瘀证)的临床疗效观察[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2015.
|
|
[38]
|
翟冰冰. 活血化瘀解毒法治疗原发性血小板增多症的临床观察[D]: [硕士学位论文]. 广州: 广州中医药大学, 2015.
|
|
[39]
|
陈信义, 麻柔, 李冬云. 规范常见血液病中医病名建议[J]. 中国中西医结合杂志, 2009, 29(11): 1040-1041.
|
|
[40]
|
赖宗浪, 史雯, 马薇, 黄晓. 李冬云运用理气活血法治疗骨髓增殖性肿瘤的临床经验[J]. 北京中医药, 2014, 33(4): 263-266.
|
|
[41]
|
周己扬, 王嫱, 刘欣, 等. 基于数据挖掘的刘宝文教授治疗骨髓增殖性疾病用药特色分析[J]. 世界中医药, 2016, 11(3): 550-553.
|
|
[42]
|
梁春灵. 李达以“血积”辨治原发性血小板增多症经验[J]. 中华中医药杂志, 2016, 31(1): 158-160.
|
|
[43]
|
冯全管. 杨文华治疗真性红细胞增多症验案1则[J]. 湖南中医杂志, 2016, 32(9): 107-108.
|
|
[44]
|
王梦亚. 原发性骨髓纤维化的中医药治疗探析[J]. 中医研究, 2016, 29(8): 9-11.
|
|
[45]
|
李达. 运用数据处理技术探讨原发性血小板增多症的中医辨证和用药规律[J]. 医学研究与教育, 2015, 32(5): 29- 34.
|